Source: GlobeNewswire Inc.
Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs, announced today that it priced an underwritten public offering of 3,300,000 of its ordinary shares at a price to the public of $37.00 per ordinary share, before the underwriting discount. All of the ordinary shares in the offering were sold by Prothena. In addition, Prothena has granted the underwriters a 30-day option to purchase up to an additional 495,000 of its ordinary shares.
Net proceeds to Prothena from the ordinary shares to be sold by Prothena in the offering are expected to be $114.2 million, after deducting the underwriting discount and estimated offering expenses, but excluding any exercise of the underwriters' option to purchase additional ordinary shares. The offering is expected to close on April 13, 2015, subject to customary closing conditions.
Credit Suisse, RBC Capital Markets and UBS Investment Bank are acting as joint book-running managers, and Oppenheimer & Co., Wedbush PacGrow, Ladenburg Thalmann and LifeSci Capital are acting as co-managers for the offering.
Recent PRTA News
- Prothena to Participate in Upcoming Healthcare Conferences • Business Wire • 08/29/2024 08:05:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/08/2024 09:13:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:14:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:09:02 PM
- Prothena Reports Second Quarter 2024 Financial Results and Business Highlights • Business Wire • 08/08/2024 08:05:00 PM
- Prothena to Report Second Quarter 2024 Financial Results on August 8 • Business Wire • 08/01/2024 08:05:00 PM
- Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration • Business Wire • 05/28/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 08:42:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 08:37:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 08:29:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:08:55 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:19:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:09:01 PM
- Prothena Reports First Quarter 2024 Financial Results and Business Highlights • Business Wire • 05/08/2024 08:05:00 PM
- Prothena to Report First Quarter 2024 Financial Results on May 8 • Business Wire • 05/01/2024 08:05:00 PM
- Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma • Business Wire • 04/15/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 02:03:16 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 02:01:40 AM
- Prothena to Participate in Upcoming Healthcare Conferences • Business Wire • 03/05/2024 09:05:00 PM
- Prothena Appoints David Ford to Newly Created Chief People Officer Position • Business Wire • 03/04/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 02:11:54 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 02:09:37 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 02:08:29 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 02:06:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 02:03:58 AM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM